CRISPR Therapeutics AG is a pioneering biotechnology company focused on translating CRISPR/Cas9 gene-editing technology into transformative therapies for serious diseases. The company's business model centers on both ex vivo and in vivo therapeutic approaches, targeting hemoglobinopathies, oncology, regenerative medicine, and autoimmune diseases. Its flagship product, CASGEVY (exagamglogene autotemcel), co-developed and co-commercialized with Vertex Pharmaceuticals, is the first approved CRISPR-based therapy, designed as a one-time functional cure for sickle cell disease and transfusion-dependent beta thalassemia. Beyond its lead asset, CRISPR Therapeutics is advancing a broad pipeline that includes allogeneic CAR-T cell therapies for hematological and solid tumors, as well as stem-cell-derived regenerative medicine programs for type 1 diabetes, bolstered by its 2022 acquisition of ViaCyte. The company generates revenue primarily through strategic collaborations, milestone payments, and product revenues tied to CASGEVY's commercialization. Geographically, CRISPR Therapeutics is domiciled and headquartered in Switzerland, with significant research and development operations in Cambridge, Massachusetts, and additional business offices in the United States and the United Kingdom. The company's competitive position is underpinned by its foundational intellectual property in CRISPR/Cas9 technology, its proven ability to navigate complex regulatory pathways to commercialization, and its strategic partnerships with major pharmaceutical companies.
